The California-based company, founded in 1983, is engaged in the discovery and development of infectious disease therapies to improve human health. Their product pipeline includes projects targeting Hepatitis C virus infection, an investigational vaccine for hepatitis E virus being developed by GlaxoSmithKline, and Prestara, an investigational drug for systemic lupus erythematosus. Genelabs Technologies has established license and collaboration agreements with prominent organizations like Novartis Institutes for BioMedical Research, National Health Research Institutes, and Genovate Biotechnology Co., Ltd. These partnerships aim to discover and develop compounds that target the hepatitis C virus. In 2009, Genelabs Technologies was acquired by SmithKline Beecham Corporation.